Aman Mansoor M, Ibrahim Yussr M, Buluk Figueira Merve, Chitneni Ahish, Mahmoud Ammar
Department of Anesthesiology, Division of Pain Medicine, Advocate Health, Oshkosh, WI, USA.
Department of Anesthesiology, Division of Pain Medicine, Northern Light Eastern Maine Medical Center, Bangor, ME, USA.
J Pain Res. 2024 Sep 5;17:2929-2936. doi: 10.2147/JPR.S468078. eCollection 2024.
This retrospective review evaluates pain and patient-defined functional goal improvement utilizing bipolar peripheral nerve stimulation (PNS) in chronic neuropathic and nociceptive pain states.
Our dataset includes 24 patients who underwent implantation of a permanent peripheral nerve stimulator from January 2018 through December 2022. A total of 29 leads were implanted amongst 24 patients, with 5 patients having leads at 2 different dermatomes. Fifteen leads were placed for primarily neuropathic pain, and 14 leads were placed for nociceptive pain. Inclusion criteria were the following: pain duration greater than 6 months, documented peri-procedural Numerical Pain Rating Scale (NPRS) and greater than 60 days follow-up post implant.
Data was collected and analyzed showing that 89.6% of implants at 6 months follow-up and 70% at 12 months follow-up achieved 50% or greater pain relief. A significant reduction in NPRS scores when comparing pre-procedure pain scores (Median = 7, n = 29) to 6-month follow-up data (Median = 2, n = 29), <0.001 with a large effect size, = 0.61. Ninety-three percent of patients reported achieving their personal functional goal. Twelve of the fourteen (86%) leads implanted for primary nociceptive pain and fourteen of the fifteen (93%) leads implanted for neuropathic pain achieved ≥50% relief at 6 months. At twelve months, seven leads in each group provided ≥50% sustained pain relief. Of the 14 patients that were on opioids, 6 discontinued, while another 2 had a reduction in oral morphine milligram equivalents (MME) at the 12-month follow-up.
This retrospective review demonstrates the potential clinical application of PNS in both nociceptive and neuropathic pain states. Further prospective studies are warranted to validate the effectiveness of PNS in the treatment of refractory nociceptive and neuropathic pain states.
本回顾性研究评估在慢性神经性疼痛和伤害性疼痛状态下,利用双极周围神经刺激(PNS)改善疼痛及患者定义的功能目标。
我们的数据集包括2018年1月至2022年12月期间接受永久性周围神经刺激器植入的24例患者。24例患者共植入29根电极,其中5例患者在2个不同皮节植入电极。15根电极用于原发性神经性疼痛,14根电极用于伤害性疼痛。纳入标准如下:疼痛持续时间超过6个月,记录围手术期数字疼痛评分量表(NPRS)且植入后随访超过60天。
收集并分析的数据显示,6个月随访时89.6%的植入电极和12个月随访时70%的植入电极实现了50%或更大程度的疼痛缓解。将术前疼痛评分(中位数 = 7,n = 29)与6个月随访数据(中位数 = 2,n = 29)进行比较时,NPRS评分显著降低,<0.001,效应量较大, = 0.61。93%的患者报告实现了个人功能目标。用于原发性伤害性疼痛的14根电极中的12根(86%)以及用于神经性疼痛的15根电极中的14根(93%)在6个月时实现了≥50%的疼痛缓解。在12个月时,每组有7根电极提供了≥50%的持续疼痛缓解。在14例服用阿片类药物的患者中,6例停药,另有2例在12个月随访时口服吗啡毫克当量(MME)减少。
本回顾性研究证明了PNS在伤害性疼痛和神经性疼痛状态中的潜在临床应用。有必要进行进一步的前瞻性研究以验证PNS在治疗难治性伤害性疼痛和神经性疼痛状态中的有效性。